Acquisition by Sung Lee of 40000 shares of Vir Biotechnology subject to Rule 16b-3
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
Filed transaction by Vir Biotechnology Officer Evp Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
MorphoSys is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
| EWTX | Edgewise Therapeutics | 18.36 | ||||
| LYRA | Lyra Therapeutics | 5.56 | ||||
| IMRX | Immuneering Corp | 5.49 | ||||
| NVCT | Nuvectis Pharma | 3.62 | ||||
| PCVX | Vaxcyte | 2.02 | ||||
| IMCR | Immunocore Holdings | 1.45 | ||||
| ELVN | Enliven Therapeutics | 0.65 | ||||
| CGEM | Cullinan Oncology | 0.43 | ||||
| ACLX | Arcellx | 0.45 | ||||
| REPL | Replimune | 0.56 | ||||
| PMVP | Pmv Pharmaceuticals | 1.27 | ||||
| VTYX | Ventyx Biosciences | 1.32 | ||||
| CCCC | C4 Therapeutics | 1.60 | ||||
| KRON | Kronos Bio | 2.04 | ||||
| MLYS | Mineralys Therapeutics, | 2.22 | ||||
| IPSC | Century Therapeutics | 2.40 | ||||
| GBIO | Generation Bio | 2.52 | ||||
| GLUE | Monte Rosa | 2.95 | ||||
| MRSN | Mersana Therapeutics | 3.72 | ||||
| RLYB | Rallybio Corp | 4.63 | ||||
| GOSS | Gossamer Bio | 7.53 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |